Abstracts (HTML) List of Authors

Kajdácsi, E

Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients

Kämpfe, D

Treatment of immune thrombocytopenia (ITP) with Eltrombopag – results of the 3 rd interim analysis of the German non-interventional trial RISA. Focussing on steroid-pretreatment and fatigue

Kampmann, P

AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirms Stable FIX Expression and Sustained Reductions in Bleeding for up to 5 Years

Kathemann, S

Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

Kaufeld, J

Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

Kemkes-Matthes, B

Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

Kenet, G

Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors

Kentouch, K

Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

Key, NS

Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial

Kichou, S

Long-term Efficacy and Safety of Fitusiran in Participants with Hemophilia A and B: An Interim Analysis of the Phase 1/2 Open-Label Extension Study

Kistner, S

The Innovative Factor VIII Molecules HAT and HAT RI Overcome Impairments of Hemophilia A Therapy

Kiszel, P

Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients

Klamroth, R

Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
Monitoring pain and joint health in patients with haemophilia
Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication
Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors
AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirms Stable FIX Expression and Sustained Reductions in Bleeding for up to 5 Years
LMWH or DOACs for cancer associated thrombosis (CAT) in daily clinical practice ? – Insights from the GECAT registry

Klauser-Braun, R

Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm

Kletzmayr, J

Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm

Knabbe, C

Von Willebrand factor ratio as a risk factor for bleeding in aortic valve stenosis replacement surgery
Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

Knöbl, P

Prevalence and clinical impact of reduced FXII activity in patients receiving extracorporeal membrane oxygenation

Knöbl, PN

Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

Knöfler, R

Laboratory phenotype variability in genetically proven von Willebrand disease type 2B

Knoll Machado, S

In vitro characterization of K5A and K5R variants of Factor IX

Knoops, K

Platelet-derived chemokines regulating neutrophil activation stages in arterial thrombus formation

Knüttgen, F

Von Willebrand factor ratio as a risk factor for bleeding in aortic valve stenosis replacement surgery
Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

Ko, RH

An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

Koenen, R

Platelet-derived chemokines regulating neutrophil activation stages in arterial thrombus formation

Kohler, TP

Antibodies protect platelet damage by pneumolysin

Kohli, S

Factor Xa and factor IIa inhibitors differentially regulate inflammation in myocardial ischemia reperfusion injury
LMWH prevents platelet and extracellular vesicle mediated thrombo-inflammation

Königs, C

Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

Königsbrügge, O

Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation
Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm

Konstantinides, SV

Intracranial involvement and neurologic manifestations in Lemierre syndrome: analysis of 712 patients.

Kouta, A

A Comparison of Functional Methods with Absolute Quantification of Heparin Levels in Clinical Samples by Heparin Red Assay
Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.
Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.
Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.

Kraemer, R

A Comparison of Functional Methods with Absolute Quantification of Heparin Levels in Clinical Samples by Heparin Red Assay
Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.

Kraemmer, D

Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation

Kragh, T

A novel approach to laboratory assessment of platelet von Willebrand factor

Krammer-Steiner, B

Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication

Kranzhöfer, D

Type 2B von Willebrand disease – a rare cause of neonatal thrombocytopenia

Kraushaar, T

In vitro characterization of K5A and K5R variants of Factor IX

Kremer Hovinga, J

Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors

Kremer Hovinga, J-A

Upregulated autophagy in antigen-presenting splenic cells hints at promotion of immune-mediated thrombotic thrombocytopenic purpura (iTTP)

Kretzschmar, A

Anticoagulation practice of cancer-associated thrombosis in the outpatient sector of Germany

Krohn-Grimberghe, M

Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

Krstic, M

Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

Krueger, I

Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets

Kruzhkova, I

Efficacy and Safety of Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials
Human Fibrinogen Concentrate for Bleeding Prophylaxis During Surgery in Paediatric Patients with Congenital Fibrinogen Deficiency

Kuebler, P

An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

Kurnik, K

Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research
A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

Kurz, H

Light-induced ion influx triggers megakaryocyte polarization